Yutaka Saisho Selected Research

peramivir

1/2021	Improvement of respiratory symptoms and health-related quality of life with peramivir in influenza patients with chronic respiratory disease: Additional outcomes of a randomized, open-label study.
1/2021	Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.
1/2019	The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
1/2018	Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
1/2017	Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
1/2017	Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yutaka Saisho Research Topics

Disease

8	Human Influenza (Influenza) 01/2021 - 01/2014
6	Infections 01/2021 - 01/2018
2	Fever (Fevers) 01/2021 - 01/2018
1	Asthma (Bronchial Asthma) 01/2021
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2021
1	Cough 01/2021
1	Healthcare-Associated Pneumonia 01/2019
1	Coinfection 01/2019
1	Herpesviridae Infections (Herpesvirus Infection) 01/2017
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017
1	Pneumonia (Pneumonitis) 01/2017
1	Respiratory Tract Infections (Respiratory Tract Infection) 02/2010

Drug/Important Bio-Agent (IBA)

6	peramivirIBA 01/2021 - 01/2017
6	Neuraminidase (Sialidase)IBA 01/2021 - 01/2017
5	Oseltamivir (Tamiflu)FDA Link 01/2021 - 01/2017
2	laninamivirIBA 01/2019 - 01/2018
2	CefiderocolIBA 01/2019 - 01/2018
2	Zanamivir (Relenza)FDA Link 01/2019 - 01/2018
1	Pharmaceutical PreparationsIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	VaccinesIBA 01/2019
1	Carbapenems (Carbapenem Antibiotics)IBA 01/2018
1	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2018
1	SiderophoresIBA 01/2018
1	C-Reactive ProteinIBA 01/2014
1	MacrolidesIBA 02/2010
1	EDP 420IBA 02/2010